Court Victory and Fresh Funding Propel Growth at Liquidia Corporation

Liquidia Corporation (NASDAQ:LQDA) is one of the 11 Best Short Squeeze Stocks to Buy Now.

Price targets raised by analysts following a favorable court ruling and receipt of funding under the HCR agreement.

Located in North Carolina, Liquidia Corporation (NASDAQ:LQDA) develops and commercializes treatments for rare cardiopulmonary diseases. With YUTREPIA™ (inhaled treprostinil powder) as its lead product, the company gained FDA approval for its use in the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. For targeted drug delivery, the company leverages proprietary PRINT® nanoparticle technology.

Following a favorable court ruling, Liquidia Corporation (NASDAQ:LQDA) commenced the first commercial sale of its pulmonary hypertension treatment, YUTREPIA™, and received an additional $50 million under its sixth amendment to its financing agreement (HCR Agreement) with Healthcare Royalty (HCRx).

Liquidia Corporation (NASDAQ:LQDA) has so far received a total of $175 million of the $200 million in potential funding, as per the HCR agreement terms. If the company manages an aggregate net sale of YUTREPIA of more than $100 million at any time on or prior to June 30, 2026, it could receive an additional $25million based on mutual agreement between the parties.

Following these developments, many analysts have raised the price target on the company’s stock. For instance, Bank of America recently raised the price target from $23 to $35, signaling a strong confidence in the company’s growth potential.

The short float of 32.39% creates a potential for rapid upside for Liquidia Corporation (NASDAQ:LQDA)’s shareholders, in the event of positive catalysts.

While we acknowledge the potential of LQDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon

Disclosure. None.